I am a
Home I AM A Search Login

Papers of the Week


2022 Nov 26


Respir Med


206

Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study.

Authors

Thelen JC, van Zelst CM, van Brummelen SE, Rauh S, In 't Veen JCCM, Kappen JH, Braunstahl G-J
Respir Med. 2022 Nov 26; 206:107058.
PMID: 36462399.

Abstract

Dupilumab as add-on treatment for severe uncontrolled asthma (SA) has shown to be effective and safe by phase-III-trials. Real-world data on clinical efficacy and safety is limited.